Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
M.D. Anderson Cancer Center
45 participants
Jul 16, 2024
OBSERVATIONAL
Summary
Cohort 1: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN). Cohort 2: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN) and to test a certain type of experimental neuromodulation (stimulation of the brain) with a device called a closed-loop brain-computer interface (clBCI) to see if can help to prevent pain due to CIPN.
Eligibility
Inclusion Criteria6
- Participants must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements.
- ECOG Performance Status of 0-2;
- Willing to come to MD Anderson for the imaging sessions.
- Are 18 years of age or above.
- Have a diagnosis of breast cancer.
- will receive chemotherapy including doxorubicin, cyclophosphamide, docetaxel, or paclitaxel;
Exclusion Criteria6
- Participants who are taking any antipsychotic medications.
- With active CNS disease, such as clinically evident metastases or leptomeningeal disease, dementia, or encephalopathy.
- Have ever been diagnosed with bipolar disorder or schizophrenia.
- Known, previously diagnosed peripheral neuropathy from causes other than chemotherapy; and
- A history of head injury or who have known seizure activity, or with a prior history of chemotherapy.
- Patients who will be administered ddAC->T.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Measure the electrical activity of your brain before you receive chemotherapy treatment and once monthly for a maximum of 6 measurements.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06389721